At a glance
- Originator AstraZeneca
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Heart failure; Pulmonary hypertension
Most Recent Events
- 09 Dec 1999 Discontinued-I for Pulmonary hypertension in United Kingdom (PO)
- 09 Dec 1999 Discontinued-Preclinical for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 09 Dec 1999 Discontinued-Preclinical for Heart failure in United Kingdom (PO)